Innovator国际已开发动力缓冲主动型ETF-3月 IMAR 深 沪
已收盘 02-06 16:00:00 美东时间
30.2948
+0.065
+0.22%
华盛通- 最 高30.32
- 今 开30.30
- 成交量 1.46万股
- 最 低 30.27
- 昨 收 30.2297
- 总市值 3408.17万
- 52周最高 30.32
- 市盈率 静 --
- 换手率 1.30%
- 52周最低 24.6018
- 委 比 -33.33%
- 总股本 112.50万
- 历史最高 30.32
- 量 比 2.01
- 振 幅 0.17%
- 历史最低 24.6018
- 每 手 1
- 风险率 1.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-FDA Approves Label Update For Kite’S Yescarta® For Relapsed/Refractory Primary Central Nervous System Lymphoma
BRIEF-FDA Approves Label Update For Kite’S Yescarta® For Relapsed/Refractory Primary Central Nervous System Lymphoma Feb 6 (Reuters) - Gilead Sciences Inc GILD.O : FDA APPROVES LABEL UPDATE FOR KITE’S YESCARTA® FOR RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA Source text: ID:nBw7Xk1Y4
02-06 21:32
BRIEF-Satellos Announces Pricing Of Us$50 Million Public Offering In Canada And The United States
BRIEF-Satellos Announces Pricing Of Us$50 Million Public Offering In Canada And The United States Feb 6 (Reuters) - Satellos Bioscience Inc MSCL.TO : SATELLOS ANNOUNCES PRICING OF US$50 MILLION PUBLIC OFFERING IN CANADA AND THE UNITED STATES SATELLOS BIOSCIENCE INC - COMMON SHARES SOLD AT US$10.10 P
02-06 21:31
Lockheed Martin Delivers Additional HIMARS Launchers to Australia
Lockheed Martin Delivers Additional HIMARS Launchers to Australia Lockheed Martin Corporation has reported continued momentum in the delivery of HIMARS launchers to U.S. and partner forces, with more than 750 units provided to date. Australia received its first HIMARS last year, and additional deliv
02-06 07:05
BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial
BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial Feb 3 (Reuters) - Pfizer Inc PFE.N : PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-
02-03 21:21
BRIEF-Exxonmobil Expects Earnings Growth Of $25 Billion Between 2024 & 2030
BRIEF-Exxonmobil Expects Earnings Growth Of $25 Billion Between 2024 & 2030 Jan 30 (Reuters) - Exxon Mobil Corp XOM.N : EXXONMOBIL - ON TRACK TO DELIVER 2030 PLAN, EXPECT ABOUT $25B EARNINGS GROWTH AND ABOUT $35B CASH FLOW GROWTH FROM 2024-2030 - PRESENTATION EXXONMOBIL OUTLOOK Q1 UPSTREAM 100 - 200
01-30 19:58
BRIEF-Sanofi's Amlitelimab Confirms Potential In Atopic Dermatitis
BRIEF-Sanofi's Amlitelimab Confirms Potential In Atopic Dermatitis Jan 23 (Reuters) - Sanofi SA SASY.PA : AMLITELIMAB CONFIRMS ITS POTENTIAL IN ATOPIC DERMATITIS AQUA AND ESTUARY STUDIES TO REPORT RESULTS IN H2 2026 AMLITELIMAB MEETS ALL PRIMARY AND SECONDARY ENDPOINTS IN SHORE STUDY Source text: ID
01-23 14:13
BRIEF-Overall Survival Primary Endpoint Met In Corcept’S Pivotal Phase 3 ROSELLA Trial Of Relacorilant In Patients With Platinum-Resistant Ovarian Cancer
BRIEF-Overall Survival Primary Endpoint Met In Corcept’S Pivotal Phase 3 ROSELLA Trial Of Relacorilant In Patients With Platinum-Resistant Ovarian Cancer Jan 22 (Reuters) - Corcept Therapeutics Inc CORT.O : OVERALL SURVIVAL PRIMARY ENDPOINT MET IN CORCEPT’S PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORIL
01-22 21:19
BRIEF-Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
Jan 23 (Reuters) - Larimar Therapeutics Inc LRMR.O: LARIMAR THERAPEUTICS ANNOUNCES DOSING OF ADOLESCENTS IN NOMLABOFUSP PEDIATRIC PHARMACOKINETIC RUN-IN STUDY FOR PATIENTS WITH FRIEDREICH’S ATAXIA LAR...
2025-01-24 06:56
BRIEF-Kantar Group Announces The Proposed Sale Of Kantar Media To H.I.G. Capital
Jan 17 (Reuters) - KANTAR GROUP: ANNOUNCED THE PROPOSED SALE OF KANTAR MEDIA TO H.I.G. CAPITAL KANTAR GROUP: TRANSACTION’S PURCHASE PRICE OF APPROXIMATELY $1 BILLION KANTAR GROUP: DEAL PRICE ANTICIPAT...
2025-01-18 07:21
BRIEF-Omeros Announces Update On Statistical Analysis Of Narsoplimab Pivotal Trial Primary Endpoint
Jan 16 (Reuters) - Omeros Corp OMER.O: OMEROS ANNOUNCES UPDATE ON STATISTICAL ANALYSIS OF NARSOPLIMAB PIVOTAL TRIAL PRIMARY ENDPOINT OMEROS CORP: SENSITIVITY ANALYSES SUPPORT RESULTS OF PRIMARY ENDPOI...
2025-01-16 22:19
